Form 4: Intellia Therapeutics EVP James Basta Reports Stock Transactions

EVP and General Counsel of Intellia Therapeutics, James Basta, reports acquisition of stock options and restricted stock units, along with a sale of shares to cover tax obligations.

Summary

• James Basta, EVP and General Counsel of Intellia Therapeutics, reported transactions involving Intellia's common stock.
• On March 1, 2025, Basta acquired 40,000 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 57,143 shares at an exercise price of $10.09.
• On March 4, 2025, Basta sold 2,572 shares at $8.99 per share to cover tax obligations related to the vesting of RSUs.
• Following these transactions, Basta directly owns 111,925 shares of Intellia Therapeutics and holds options for 57,143 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock grants are positive, but the sale, even for tax purposes, tempers the overall sentiment. It's a routine transaction.

Positives

• The grant of restricted stock units and stock options to a key executive suggests confidence in the company's future performance.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors, although it's a common practice.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term downward pressure on the stock price.

Industry Context

Stock transactions by company executives are routinely monitored as indicators of management's confidence in the company's prospects. Grants of stock options and RSUs are common forms of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Executive compensation packages including stock options and RSUs are standard practice in the biotech industry, often benchmarked against peer companies like CRISPR Therapeutics and Editas Medicine.
• The vesting schedules and exercise prices are typically structured to align executive incentives with long-term shareholder value creation.

Stakeholder Impact

• The transactions could have a minor impact on shareholders depending on how they interpret the executive's actions.
• Employees may view the stock grants as a positive sign of the company's commitment to its leadership.

Key Dates